Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. BMS
2. Eisai
3. EMD Serono
4. GSK
5. Ipsen
6. Pfizer
7. Merck
8. Novartis
9. Roche